FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232188906> ?p ?o ?g. }

• W4232188906 endingPage "1021" @default.
• W4232188906 startingPage "1012" @default.
• W4232188906 abstract "To evaluate the efficacy and safety of abiraterone acetate plus prednisone (AAP) plus androgen-deprivation therapy (ADT) in Japanese subgroup with newly diagnosed, metastatic hormone-naïve prostate cancer (mHNPC) from Phase 3, randomized, global LATITUDE study.Men with mHNPC having ≥2 of 3 high-risk factors (Gleason score ≥8, ≥3 bone lesions or measurable visceral metastases) randomly received abiraterone acetate 1000-mg+ prednisone 5-mg+ADT (AAP group) or ADT+Placebos (Placebo group). Coprimary endpoints were overall survival (OS) and radiographic progression-free survival (rPFS).Of total 1199 patients in the LATITUDE study, 70 (5.8%) were Japanese (n = 35 each in the AAP and placebo group). After a median follow-up of 35.02 months (range: 2.5-42.3), median OS was not reached in both AAP group and placebo group (HR: 0.635; 95% CI, 0.152-2.659) and the median length of rPFS was not reached in the AAP group and was 22 months in the placebo group (HR:0.219; 95% CI, 0.086-0.560). The most frequently reported adverse events (>20% in either group) in the Japanese subgroup were hypertension, nasopharyngitis, weight increased, hypokalemia, hot flush, back pain, hyperglycemia, ALT and AST elevation. The incidence of Grade 3 or 4 adverse events was 65.7% (23/35) in the AAP group and 20% (7/35) in the placebo group. The efficacy and safety findings of Japanese subgroup were consistent with that of the overall study population.Treatment with AAP plus ADT has shown a positive risk-benefit balance and may serve as a new treatment option to improve the prognosis of Japanese mHNPC patients with high-risk features." @default.
• W4232188906 created "2022-05-12" @default.
• W4232188906 creator A5007779528 @default.
• W4232188906 creator A5014625956 @default.
• W4232188906 creator A5028207252 @default.
• W4232188906 creator A5037542887 @default.
• W4232188906 creator A5041155623 @default.
• W4232188906 creator A5041265628 @default.
• W4232188906 creator A5046362015 @default.
• W4232188906 creator A5073765202 @default.
• W4232188906 creator A5080906803 @default.
• W4232188906 date "2018-10-26" @default.
• W4232188906 modified "2023-10-03" @default.
• W4232188906 title "Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study" @default.
• W4232188906 cites W1506162348 @default.
• W4232188906 cites W1977393265 @default.
• W4232188906 cites W1985233557 @default.
• W4232188906 cites W1985734141 @default.
• W4232188906 cites W2002795241 @default.
• W4232188906 cites W2007824082 @default.
• W4232188906 cites W2018291607 @default.
• W4232188906 cites W2018964568 @default.
• W4232188906 cites W2030176464 @default.
• W4232188906 cites W2043814871 @default.
• W4232188906 cites W2055346449 @default.
• W4232188906 cites W2056372790 @default.
• W4232188906 cites W2088132910 @default.
• W4232188906 cites W2110534364 @default.
• W4232188906 cites W2119285946 @default.
• W4232188906 cites W2121630225 @default.
• W4232188906 cites W2127357802 @default.
• W4232188906 cites W2128301586 @default.
• W4232188906 cites W2137467802 @default.
• W4232188906 cites W2138922286 @default.
• W4232188906 cites W2142466432 @default.
• W4232188906 cites W2148143162 @default.
• W4232188906 cites W2150418305 @default.
• W4232188906 cites W2150684196 @default.
• W4232188906 cites W2150865892 @default.
• W4232188906 cites W2158921732 @default.
• W4232188906 cites W2160286488 @default.
• W4232188906 cites W2166922670 @default.
• W4232188906 cites W2168108459 @default.
• W4232188906 cites W2178183066 @default.
• W4232188906 cites W2214621962 @default.
• W4232188906 cites W2511358444 @default.
• W4232188906 cites W2590085844 @default.
• W4232188906 cites W2620798309 @default.
• W4232188906 cites W2664930764 @default.
• W4232188906 cites W2742834257 @default.
• W4232188906 cites W2743936472 @default.
• W4232188906 cites W2783782279 @default.
• W4232188906 cites W2788841415 @default.
• W4232188906 doi "https://doi.org/10.1093/jjco/hyy129" @default.
• W4232188906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30371895" @default.
• W4232188906 hasPublicationYear "2018" @default.
• W4232188906 type Work @default.
• W4232188906 citedByCount "21" @default.
• W4232188906 countsByYear W42321889062018 @default.
• W4232188906 countsByYear W42321889062019 @default.
• W4232188906 countsByYear W42321889062020 @default.
• W4232188906 countsByYear W42321889062021 @default.
• W4232188906 countsByYear W42321889062022 @default.
• W4232188906 countsByYear W42321889062023 @default.
• W4232188906 crossrefType "journal-article" @default.
• W4232188906 hasAuthorship W4232188906A5007779528 @default.
• W4232188906 hasAuthorship W4232188906A5014625956 @default.
• W4232188906 hasAuthorship W4232188906A5028207252 @default.
• W4232188906 hasAuthorship W4232188906A5037542887 @default.
• W4232188906 hasAuthorship W4232188906A5041155623 @default.
• W4232188906 hasAuthorship W4232188906A5041265628 @default.
• W4232188906 hasAuthorship W4232188906A5046362015 @default.
• W4232188906 hasAuthorship W4232188906A5073765202 @default.
• W4232188906 hasAuthorship W4232188906A5080906803 @default.
• W4232188906 hasBestOaLocation W42321889061 @default.
• W4232188906 hasConcept C121608353 @default.
• W4232188906 hasConcept C126322002 @default.
• W4232188906 hasConcept C142724271 @default.
• W4232188906 hasConcept C168563851 @default.
• W4232188906 hasConcept C187960798 @default.
• W4232188906 hasConcept C197934379 @default.
• W4232188906 hasConcept C204787440 @default.
• W4232188906 hasConcept C27081682 @default.
• W4232188906 hasConcept C2775832370 @default.
• W4232188906 hasConcept C2777899217 @default.
• W4232188906 hasConcept C2778720950 @default.
• W4232188906 hasConcept C2780192828 @default.
• W4232188906 hasConcept C2908647359 @default.
• W4232188906 hasConcept C44249647 @default.
• W4232188906 hasConcept C71924100 @default.
• W4232188906 hasConcept C90924648 @default.
• W4232188906 hasConcept C99454951 @default.
• W4232188906 hasConceptScore W4232188906C121608353 @default.
• W4232188906 hasConceptScore W4232188906C126322002 @default.
• W4232188906 hasConceptScore W4232188906C142724271 @default.
• W4232188906 hasConceptScore W4232188906C168563851 @default.
• W4232188906 hasConceptScore W4232188906C187960798 @default.
• W4232188906 hasConceptScore W4232188906C197934379 @default.

• next